Your browser doesn't support javascript.
loading
Déjà-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task.
de Cates, Angharad N; Wright, Lucy C; Martens, Marieke A G; Gibson, Daisy; Türkmen, Cagdas; Filippini, Nicola; Cowen, Philip J; Harmer, Catherine J; Murphy, Susannah E.
Afiliação
  • de Cates AN; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK. angharad.decates@psych.ox.ac.uk.
  • Wright LC; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK. angharad.decates@psych.ox.ac.uk.
  • Martens MAG; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
  • Gibson D; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
  • Türkmen C; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
  • Filippini N; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
  • Cowen PJ; Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK.
  • Harmer CJ; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
  • Murphy SE; Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Transl Psychiatry ; 11(1): 497, 2021 10 04.
Article em En | MEDLINE | ID: mdl-34602607
Cognitive deficits commonly accompany psychiatric disorders but are often underrecognised, and difficult to treat. The 5-HT4 receptor is a promising potential treatment target for cognitive impairment because in animal studies 5-HT4 receptor agonists enhance hippocampal-dependent memory processes. To date, there has been little work translating these effects to humans. We tested whether short-term administration of the 5-HT4 partial agonist, prucalopride, modified behavioural and neural (fMRI) memory processing in 44 healthy human volunteers using an experimental medicine model. We found that participants who had received six days of prucalopride treatment were significantly better at recalling previously seen neutral images and distinguishing them from new images. At a neural level, prucalopride bilaterally increased hippocampal activity and activity in the right angular gyrus compared with placebo. Taken together, these findings demonstrate the potential of 5-HT4-receptor activation for cognitive enhancement in humans, and support the potential of this receptor as a treatment target for cognitive impairment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Serotonina / Agonistas do Receptor 5-HT4 de Serotonina Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Transl Psychiatry Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Serotonina / Agonistas do Receptor 5-HT4 de Serotonina Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Transl Psychiatry Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos